Articles

Antibody–drug conjugates are at the leading edge of innovation and efficacy in breast cancer treatment. Research efforts continue in order to establish further novel targets and thus further advance patient outcomes. Read More ›

Rush University Cancer Center in Chicago, IL, is well known for providing patients with outstanding cancer care, including immunotherapies, targeted therapies, and minimally invasive surgical options. Read More ›

The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning. Read More ›

Cancer and mental disorders have a symbiotic relationship. Read More ›

A single dose of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen–directed CAR T-cell therapy, resulted in early, deep, and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma, according to updated results from the phase 1b/2 CARTITUDE-1 clinical trial. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between September 20, 2021, and October 29, 2021. Read More ›

Early results from the CheckMate-648 clinical trial, which evaluated the efficacy and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, suggest a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC). Read More ›